References
- Abella JV, Park M (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab, 296, 973-84. https://doi.org/10.1152/ajpendo.90857.2008
- Burgess AW (2008). EGFR family: structure physiology signaling and therapeutic targets. Growth Factors, 26, 263-74. https://doi.org/10.1080/08977190802312844
- Castillo L, Etienne-Grimaldi MC, Fischel JL, et al (2004). Pharmacological background of EGFR targeting. Ann Oncol, 15, 1007-12. https://doi.org/10.1093/annonc/mdh257
- de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J (2001). c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytotic route. J Cell Science, 114, 2167-78.
- de Melker AA, van der Horst G, Borst J (2004). Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J Biol Chem, 279, 55465-73. https://doi.org/10.1074/jbc.M409765200
- El-Rayes BF, LoRusso PM (2004). Targeting the epidermal growth factor receptor. Bri J Cancer, 91, 418-24. https://doi.org/10.1038/sj.bjc.6601921
- Fukazawa T, Miyake S, Bandi V, Band H (1996). Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) Stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem, 271, 14554-9. https://doi.org/10.1074/jbc.271.24.14554
- Glogowska A, Stetefeld J, Weber E, et al (2012). Epidermal growth factor cytoplasmic domain affects erbb protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia, 14, 336-409.
- Han W, Zhang T, Yu H, Foulke JG, Tang CK (2006). Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther, 5, 1361-8. https://doi.org/10.4161/cbt.5.10.3226
- Hosaka T, Inoue F, Ando K, et al (2007). Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. Anticancer Res, 27, 2253-64.
- Huang F, Sorkin A (2005). Growth factor receptor binding protein 2 mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell, 16, 1268-81. https://doi.org/10.1091/mbc.E04-09-0832
- Huang F, Goh LK, Sorkin A (2007). EGF receptor ubiquitination is not necessary for its internalization. PNAS, 104, 16904-9. https://doi.org/10.1073/pnas.0707416104
- Jayaraman B, Valiathan GM, Jayakumar K, et al (2012). Lack of mutation in p53 and H-ras genes in phenytoin induced gingival overgrowth suggests its non cancerous nature. Asian Pac J Cancer Prev, 13, 5535-8. https://doi.org/10.7314/APJCP.2012.13.11.5535
- Kim YT, Park SW, Kim JW (2002). Correlation between expression of EGFR and the prognosis of patients with cervical cancer. Gynecol Oncol, 87, 84-9. https://doi.org/10.1006/gyno.2002.6803
- Kirisits A, Pils D, Krainer M (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. nt J Biochem Cell Biol, 39, 2173-82. https://doi.org/10.1016/j.biocel.2007.07.012
- Kirkegaard T, Jaattela M (2009). Lysosomal involvement in cell death and cancer. Biochim Biophys Acta, 1793, 746-54. https://doi.org/10.1016/j.bbamcr.2008.09.008
- Leahy DJ (2004). Structure and Function of the Epidermal Growth Factor (egf/erbb) family of receptors. Adv Protein Chem, 68, 1-27. https://doi.org/10.1016/S0065-3233(04)68001-6
- Lipkowitz S (2002). The role of the ubiquitination-proteasome pathway in breast cancer Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res, 5, 8-15. https://doi.org/10.1186/bcr541
- Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S et al (2010). Heterozygous germline mutations in the CBL tumorsuppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet, 87, 250-7. https://doi.org/10.1016/j.ajhg.2010.06.015
- McMillen E, Ye F, Li G, Wu Y, Kin G et al (2010). Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res, 36, 531-7. https://doi.org/10.3109/01902148.2010.482176
- Murugan AK, Munirajan AK, Tsuchida N (2012). Ras oncogenes in oral cancer: the past 20 years. Oral Oncol, 48, 383-92. https://doi.org/10.1016/j.oraloncology.2011.12.006
- Normanno N, De Luca A, Bianco C, et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 336, 2-16.
- Ogiso H, Ishitani R, Nureki O, et al (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110, 775-87. https://doi.org/10.1016/S0092-8674(02)00963-7
- Pennock S, Wang Z (2008). A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Molecular and Cell Biology, 28, 3020-37. https://doi.org/10.1128/MCB.01809-07
- Rajendran S, Muthupalani RS, Ramanathan A (2013). Lack of RING finger domain (RFD) Mutations of the c-Cbl gene in oral squamous cell carcinomas in Chennai, India. Asian Pac J Cancer Prev, 14, 1073-5. https://doi.org/10.7314/APJCP.2013.14.2.1073
- Rubin C, Gur G, Yarden Y (2005). Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res, 15, 66-71. https://doi.org/10.1038/sj.cr.7290268
- Sigismund S, Confalonieri S, Ciliberto A, et al (2012). Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev, 92, 273-366. https://doi.org/10.1152/physrev.00005.2011
- Soonthornthum T, Arias-Pulido H, Joste N, et al (2011). Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol, 10, 2166-78.
- Valiathan GM, Thenumgal SJ, Jayaraman B, et al (2012). Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 13, 6155-7. https://doi.org/10.7314/APJCP.2012.13.12.6155
- Visser Smit GD, Place TL, Cole SL, et al (2009). Cbl controls EGFR fate by regulating early endosome. Sci Signal, 2, 86.
- Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8, 1197-206. https://doi.org/10.1023/A:1008209720526
- Woelk T, Sigismund S, Penengo L, Polo S (2007). The ubiquitination code: a signalling problem. Cell Division, 2, 11. https://doi.org/10.1186/1747-1028-2-11
Cited by
- BRD7 Promoter Hypermethylation as an Indicator of Well Differentiated Oral Squamous Cell Carcinomas vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1615